NuCana (NCNA) shares were up 200% pre-bell Monday after the company said that a combination of NUC-7738 and pembrolizumab led to prolonged progression-free survival in a phase 2 trial for patients with metastatic melanoma.
Dermata Therapeutics (DRMA) stock was over 64% higher following a 6.8% rise in the previous session.
Exicure (XCUR) shares were up 43%, adding to Friday's 5.3% increase.
Agape ATP (ATPC) stock was 26% higher, extending Friday's rally.
Nuvalent (NUVL) shares were up nearly 16% after Friday's 7.1% rise.
Price: 7.6200, Change: +5.08, Percent Change: +200.00
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。